Focused On-demand Library for Kinesin-like protein KIF21A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Kinesin-like protein KIF2; Renal carcinoma antigen NY-REN-62

Alternative UPACC:

Q7Z4S6; A8MX28; B0I1R9; B9EGE4; F5H0C3; F5H219; Q2UVF1; Q6UKL9; Q7Z668; Q86WZ5; Q8IVZ8; Q9C0F5; Q9NXU4; Q9Y590


Kinesin-like protein KIF21A, also known as Kinesin-like protein KIF2 and Renal carcinoma antigen NY-REN-62, is a microtubule-binding motor protein. It plays a crucial role in neuronal axonal transport, moving along microtubules with a plus-end directed motor activity. This protein's function is vital for the proper functioning of neuronal cells.

Therapeutic significance:

KIF21A is implicated in congenital fibrosis of extraocular muscles type 1, a disorder characterized by restrictive ophthalmoplegia, ptosis, and backward tilt of the head. Understanding the role of Kinesin-like protein KIF21A could open doors to potential therapeutic strategies for this and related ocular motility disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.